[ad_1]
FRANKFURT (Dow Jones) – The pharmaceutical company Roche reports encouraging results from a study with its anticancer drug Tecentriq. She has shown that the drug, in combination with chemotherapy, improves the chances in patients with a particular breast cancer that the disease is not progressing. The Swiss company intends to submit data, among others, to US and European health authorities.
Immunotherapeutic cancer is already approved in the EU, USA and in more than 70 countries for some cancers.
Contact's author: [email protected]
DJG / bam / ros
(END) Dow Jones Newswires
2 July 2018 3:29 ET (07:29 GMT) [19659007] (function (d, s, id) {
var js, fjs = d.getElementsByTagName (s) [0];
if (d.getElementById (id)) returns;
js = d.createElement (s); js.id = id;
js.src = "http://connect.facebook.net/en_US/all.js#xfbml=1&status=0";
fjs.parentNode.insertBefore (js, fjs);
} (document, 'script', 'facebook-jssdk'));
[ad_2]
Source link
